IP Library Granted Patent US 11,643,432
Granted Patent B2
US 11,643,432 · App. 16/470,339 · Granted May 9, 2023

Nucleoside derivative and use thereof

Inventor: Yoshihito Ueno (Gifu, JP)
Assignee: NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM
C07H19/10C12N15/113C12N2310/141C12N2310/322
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,643,432
App. No.
16/470,339
Granted
May 9, 2023
Kind
B2
Abstract

A nucleoside derivative represented below, or a salt thereof. (In (1), R 1 represents a hydrogen atom, a hydroxyl group or a protected group, and in (2), X represent a halogen atom. In (1) and (2), R 2 and R 4 each represent a hydrogen atom, a hydroxyl protecting, phosphate, or protected phosphate group, or —P(═O) n R 5 R 6 (n is 0 or 1, R 5 and R 6 each representing a hydrogen atom, hydroxyl, protected hydroxyl, mercapto, protected mercapto, lower alkoxy, cyano lower alkoxy, amino or substituted amino group, when n is 1, R 5 and R 6 are not both hydrogen atoms), R 3 represents NHR 7 (R 7 represents a hydrogen atom, alkyl, alkenyl or protecting group for an amino group), an azide, amidino or guanidino group, each having a linking group (when R 7 is hydrogen atom, the linking group is an alkylene group), and B represents any of a purine-9-yl, 2-oxo-pyrimidin-1-yl, substituted purine-9-yl or substituted 2-oxo-pyrimidin-1-yl group).

Claims (38)

1. An oligonucleotide comprising a nucleoside derivative represented by formula (2) below, or a salt thereof,

wherein:

X represents a fluorine atom,

R 2 and R 4 may be the same or different, and each represents:

a hydrogen atom,

a hydroxyl protecting group,

a phosphate group,

a protected phosphate group, or

—P(═O) n R 5 R 6 in which n is 0 or 1, and R 5 and R 6 may be the same or different, with each representing a hydrogen atom, hydroxyl group, protected hydroxyl group, mercapto group, protected mercapto group, lower alkoxy group, cyano lower alkoxy group, amino group or substituted amino group, but when n is 1, R 5 and R 6 are not both hydrogen atoms,

R 3 represents:

NHR 7 in which R 7 represents a hydrogen atom, an alkyl group, an alkenyl group or a protecting group for an amino group,

an azide group,

an amidino group, or

a guanidino group,

each having a linking group, but when R 7 is hydrogen atom or a protecting group for an amino group, the linking group is an alkylene group which has 2 to 3 carbon atoms, and

B represents a nucleobase.

2. The oligonucleotide of claim 1 , wherein said oligonucleotide is selected from the group consisting of a DNA molecule, a RNA molecule, and a duplex comprising a DNA and/or a RNA molecule.

3. The oligonucleotide of claim 1 , wherein said oligonucleotide comprises a nucleoside derivative represented by the structure:

4. An RNA molecule comprising an oligoribonucleotide derivative represented by formula (2) below, or a salt thereof,

wherein:

X represents a fluorine atom,

R 2 and R 4 may be the same or different, and each represents:

a hydrogen atom,

a hydroxyl protection group,

a phosphate group,

a protected phosphate group, or

—P(═O) n R 5 R 6 in which n is 0 or 1, and R 5 and R 6 may be the same or different, with each representing a hydrogen atom, hydroxyl group, protected hydroxyl group, mercapto group, protected mercapto group, lower alkoxy group, cyano lower alkoxy group, amino group or substituted amino group, but when n is 1, R 5 and R 6 are not both hydrogen atoms,

R 3 represents:

NHR 7 in which R 7 represents a hydrogen atom, an alkyl group, an alkenyl group or a protecting group for an amino group,

an azide group,

an amidino group, or

a guanidino group,

each having a linking group, but when R 7 is hydrogen atom, the linking group is an alkylene group which has 2 to 3 carbon atoms, and

B represents any of a purine-9-yl group, 2-oxo-pyrimidin-1-yl group, substituted purine-9-yl group or substituted 2-oxo-pyrimidin-1-yl group; and

wherein said RNA molecule consists of an RNA interference agent.

5. The RNA molecule of claim 4 , wherein said RNA molecule consists of a siRNA.

6. The RNA molecule according to claim 4 , wherein R 7 represents a hydrogen atom.

7. The RNA molecule according to claim 4 , wherein the nucleoside derivative comprises the structure:

Assignments (2)
MERGER Recorded Apr 14, 2022
From: GIFU UNIVERSITY
To: NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM
Reel/Frame 059715/0153 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2019
From: UENO, YOSHIHITO
To: GIFU UNIVERSITY
Reel/Frame 049484/0294 →
Priority Claims (1)
JP JP2016-244916 · Dec 16, 2016 · national
Continuity (1)
Related Publication 20210371447A1 · Dec 2, 2021